The U.S. Food and Drug Administration (FDA) has approved Cymbalta(R) (duloxetine HCl) for the maintenance treatment of generalized anxiety disorder (GAD) in adults, Eli Lilly and Company (NYSE: LLY) announced today.
“Since generalized anxiety disorder can be a chronic illness, it is important that doctors and their patients find a treatment option that is effective [...] www.apothekersnieuws.nl/...reatment-of-generalized-anxiety-disorder/3854/ - 1 Dec 2009
Printen
Doorsturen